Skip to content

Treatment of Chronic Stroke With IpsiHand

A Brain Computer Interface and Brain-Controlled Stroke Rehabilitation Method Utilizing Electroencephalography in Hemiparetic and Hemiplegic Stroke Patients to Achieve Thought Control of Machines and a Better Understanding of Brain Function

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02552368
Enrollment
23
Registered
2015-09-17
Start date
2012-08-31
Completion date
2015-11-30
Last updated
2018-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

Stroke Rehabilitation, BCI, Stroke, Upper Extremity Rehabilitation, paresis, hemiparesis

Brief summary

The ultimate goal of this project is to develop a functioning and clinically feasible method for restoring function to motor-impaired stroke survivors. This ultimate goal will be approached through two different means. The first method is to develop a functioning brain-computer interface that operates based on cortical activity ipsilateral to an intended movement on the motor-impaired side of the body. And secondly, to develop new methods of rehabilitation that involve stimulating peripheral muscles based upon cortical activity ipsilateral to intended movements. Finally, the study seeks to assess changes in functional connectivity as a result of using a BCI device.

Detailed description

This study will be carried out in two phases designed to achieve the objectives described above. The first phase will determine the feasibility of recording ipsilateral (contralesional) motor commands and use the signals to control a computer. This phase will involve recording EEG signals during the performance of real and imagined motor movements of both the impaired and non-impaired hand in stroke survivors. After recording the signals and analyzing the data, the signals will be used to try to control a cursor on a computer screen or a robotic hand. The second phase of the study will determine if the BCI system can be used to impact rehabilitation. Motor commands would be performed as in phase 1 to determine the accompanying EEG signals. The EEG signals would then be used to control stimulation of the impaired limb. Rehabilitation would be assessed by examining changes in commonly used functional motor scores. The ultimate goal of this project is to develop a functioning and clinically feasible method for restoring function to motor-impaired stroke survivors. This ultimate goal will be approached through two different means. The first method is to develop a functioning brain-computer interface that operates based on cortical activity ipsilateral to an intended movement on the motor-impaired side of the body. And secondly, to develop new methods of rehabilitation that involve stimulating peripheral muscles based upon cortical activity ipsilateral to intended movements. Finally, the study seeks to assess changes in functional connectivity as a result of using a BCI device.

Interventions

DEVICEIpsiHand Device

Once a participant has completed (3) EEG Signal Screens and (2) separate set of baseline measurements, the IpsiHand BCI Device is provided to participants to use a minimum of (5) out of (7) days a week for a total duration of 12 weeks. Participants are seen bi-weekly throughout the duration of the trial to assess affected upper extremity and assess functional impact. At the completion of 12 weeks of device use, the participants complete a set of measurements to assess function of the affected upper extremity.

Sponsors

Washington University School of Medicine
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 88 Years
Healthy volunteers
Yes

Inclusion criteria

* 6 months post stroke * Modified Ashworth Scale of 1+ or less of elbow flexion in the affected upper extremity * Short Blessed Test Score of 8 or less * Unstructured Mesulam with 2 or less omissions

Exclusion criteria

* Dementia * Severe spasticity in affected upper extremity * Unilateral Visual Inattention (neglect) * Contracture(s) in the affected upper extremity * Botox injections administered within 9 months * Aphasia which limits effective communication

Design outcomes

Primary

MeasureTime frameDescription
Change in Action Research Arm Test (ARAT) ScoreBaseline and 12 weeksThe Action Research Arm Test (ARAT) is an evaluative measure to assess specific changes in limb function among individuals who sustained cortical damage resulting in hemiplegia (Lyle, 1981). It assesses a client's ability to handle objects differing in size, weight and shape and therefore can be considered to be an arm-specific measure of activity limitation (Platz, Pinkowski, Kim, di Bella, & Johnson, 2005). The ARAT's is a 19 item measure divided into 4 sub-tests (grasp, grip, pinch, and gross arm movement). Performance on each item is rated on a 4-point ordinal scale ranging from: 3\) Performs test normally 2) Completes test, but takes abnormally long or has great difficulty 1\) Performs test partially 0) Can perform no part of test The maximum score achievable on this measure is 57 points.

Secondary

MeasureTime frameDescription
Canadian Occupational Performance Measure (COPM)Baseline and 12 weeksThe COPM is an evidence-based outcome measure designed to capture a client's self-perception of performance in 5 patient-identified tasks over time. Patients identified 5 functional activities that they wanted to perform more independently or with greater ease. COPM measurements consisted of a semi-structured interview in which patients rated their performance & satisfaction with each activity on an ordinal scale from 1 to 10. A performance score of 1 indicated they are unable to perform identified task, & a score of 10 indicates they are able to complete the functional task as easy as prior to stroke. A satisfaction score of 1 indicated they were not satisfied at all to 10 indicating they are extremely satisfied with how they complete the identified functional task. Patients would rate (5) functional tasks for their performance and satisfaction. Scores were averaged between the scores from the 5 functional activities.

Countries

United States

Participant flow

Participants by arm

ArmCount
Experimental
IpsiHand is a device which includes a robotic glove that you wear on your hand and a headset that you wear on your head. The headset picks up your thoughts and sends them to the robotic glove, to control opening and closing of your hand. IpsiHand Device: Once a participant has completed (3) EEG Signal Screens and (2) separate set of baseline measurements, the IpsiHand BCI Device is provided to participants to use a minimum of (5) out of (7) days a week for a total duration of 12 weeks. Participants are seen bi-weekly throughout the duration of the trial to assess affected upper extremity and assess functional impact. At the completion of 12 weeks of device use, the participants complete a set of measurements to assess function of the affected upper extremity.
10
Total10

Baseline characteristics

CharacteristicExperimental
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
4 Participants
Age, Categorical
Between 18 and 65 years
6 Participants
Age, Continuous58.6 years
STANDARD_DEVIATION 10.3
Race and Ethnicity Not Collected— Participants
Region of Enrollment
United States
10 participants
Sex: Female, Male
Female
1 Participants
Sex: Female, Male
Male
9 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 23
serious
Total, serious adverse events
0 / 23

Outcome results

Primary

Change in Action Research Arm Test (ARAT) Score

The Action Research Arm Test (ARAT) is an evaluative measure to assess specific changes in limb function among individuals who sustained cortical damage resulting in hemiplegia (Lyle, 1981). It assesses a client's ability to handle objects differing in size, weight and shape and therefore can be considered to be an arm-specific measure of activity limitation (Platz, Pinkowski, Kim, di Bella, & Johnson, 2005). The ARAT's is a 19 item measure divided into 4 sub-tests (grasp, grip, pinch, and gross arm movement). Performance on each item is rated on a 4-point ordinal scale ranging from: 3\) Performs test normally 2) Completes test, but takes abnormally long or has great difficulty 1\) Performs test partially 0) Can perform no part of test The maximum score achievable on this measure is 57 points.

Time frame: Baseline and 12 weeks

ArmMeasureValue (MEAN)Dispersion
Change in ARAT From Baseline to 12 Weeks of BCI Device UseChange in Action Research Arm Test (ARAT) Score6.2 units on a scaleStandard Deviation 4.4
p-value: 0.002Paired t-Test
Secondary

Canadian Occupational Performance Measure (COPM)

The COPM is an evidence-based outcome measure designed to capture a client's self-perception of performance in 5 patient-identified tasks over time. Patients identified 5 functional activities that they wanted to perform more independently or with greater ease. COPM measurements consisted of a semi-structured interview in which patients rated their performance & satisfaction with each activity on an ordinal scale from 1 to 10. A performance score of 1 indicated they are unable to perform identified task, & a score of 10 indicates they are able to complete the functional task as easy as prior to stroke. A satisfaction score of 1 indicated they were not satisfied at all to 10 indicating they are extremely satisfied with how they complete the identified functional task. Patients would rate (5) functional tasks for their performance and satisfaction. Scores were averaged between the scores from the 5 functional activities.

Time frame: Baseline and 12 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Change in ARAT From Baseline to 12 Weeks of BCI Device UseCanadian Occupational Performance Measure (COPM)Performance1.56 units on a scaleStandard Deviation 1.7
Change in ARAT From Baseline to 12 Weeks of BCI Device UseCanadian Occupational Performance Measure (COPM)Satisfaction1.54 units on a scaleStandard Deviation 1.86
Comparison: Signed-Rank Test for Performance COPM between Baseline and 12 weeksp-value: 0.022Wilcoxon (Mann-Whitney)
Comparison: Signed-Rank Test for Satisfaction COPM between Baseline and 12 weeksp-value: 0.031Wilcoxon (Mann-Whitney)

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026